Petrelintide
Also known as: ZP8396, Long-acting amylin analog
Petrelintide (also called ZP8396 or Long-acting amylin analog) is an investigational amylin analog. Petrelintide is a long-acting amylin receptor agonist in clinical development, engineered for stability and once-weekly administration. It engages amylin and calcitonin receptor complexes in hindbrain nuclei, principally the area postrema, where amylin signalling slows gastric emptying and reduces meal size.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- Long-acting (once-weekly; precise human t½ not yet widely published)
- FDA status
- Investigational New Drug (IND)
- Administration Route
- Subcutaneous
- Frequency
- Weekly
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Amylin receptor
Research summary
Investigational long-acting amylin receptor agonist from Zealand Pharma, engineered for once-weekly dosing and in clinical development for obesity. Amylin agonists reduce food intake through hindbrain pathways separate from incretin signalling, so they are being studied both alone and alongside GLP-1 receptor agonists. Not FDA-approved.
Peptide Library's Petrelintide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Per trial protocol
- Frequency
- Weekly
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Timing Notes
- Phase 2b (ZUPREME-1) in obesity
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Petrelintide is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| Half-life | Long-acting (once-weekly; precise human t½ not yet widely published) |
| Appearance | Investigational sc formulation |
| Formulation | Lyophilized Powder |
| PubChem CID | 172915807 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Petrelintide is a long-acting amylin receptor agonist in clinical development, engineered for stability and once-weekly administration. It engages amylin and calcitonin receptor complexes in hindbrain nuclei, principally the area postrema, where amylin signalling slows gastric emptying and reduces meal size. The developmental thesis for amylin agonists is that they reduce food intake through a mechanism distinct from incretin signalling, potentially with a different tolerability profile, and can be used alone or alongside a GLP-1 receptor agonist. Efficacy and safety remain under investigation and it is not approved for any use.
Origin
Synthetic long-acting amylin analog.
Targets
Studies
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
Regulatory & research status
Petrelintide has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
Benefits
Petrelintide side effects
Side Effects
- Nausea
- GI effects
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Petrelintide: frequently asked questions
What is Petrelintide?
Investigational long-acting amylin receptor agonist from Zealand Pharma, engineered for once-weekly dosing and in clinical development for obesity. Amylin agonists reduce food intake through hindbrain pathways separate from incretin signalling, so they are being studied both alone and alongside GLP-1 receptor agonists. Not FDA-approved.
How does Petrelintide work?
Petrelintide is a long-acting amylin receptor agonist in clinical development, engineered for stability and once-weekly administration. It engages amylin and calcitonin receptor complexes in hindbrain nuclei, principally the area postrema, where amylin signalling slows gastric emptying and reduces meal size.
Is Petrelintide FDA approved?
No. Petrelintide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What is the half-life of Petrelintide?
Reported half-life for Petrelintide is Long-acting (once-weekly; precise human t½ not yet widely published). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Petrelintide banned in sport?
Petrelintide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Petrelintide?
Compounds most often compared with Petrelintide include Cagrilintide, Pramlintide, CagriSema and Amycretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials — Diabetes Obes Metab, 2026External reference
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue — J Med Chem, 2025External reference
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies — Vascul Pharmacol, 2026External reference
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes — Peptides, 2026External reference
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs — Pharmacol Res, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Petrelintide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Petrelintide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →